Cholesterol depletion or synthesis inhibition has been considered as a potential therapeutic target for cancers, including lung cancer, which is supported by the protective effect of lower CETP on lung cancer risk found in our study20–24. For both diseases, there is however limited information on the potential differences between ancestries of altered lipid metabolism or CETP metabolism specifically. This evidence concerns the gene CETP and lung cancer.